


March 25th, 2021

02:00 p.m.



Translational Research and  
Advanced Imaging Laboratory

# Conference

*MR metabolic imaging of neurological disorders*



## Prof. Myriam CHAUMEIL

Associate Professor in Residence

Physical Therapy and Rehabilitation Science/

Radiology & Biomedical Imaging

University of California San Francisco

### Contact

Yannick Crémillieux

ISM, University of Bordeaux

yannick.cremillieux@u-bordeaux.fr



## Zoom Webinar

<https://bit.ly/3r5stWH>

[trail.labex.u-bordeaux.fr](http://trail.labex.u-bordeaux.fr)

université  
de BORDEAUX



Inserm



**Myriam M. Chaumeil** is an Associate Professor in Residence in the department of Physical Therapy & Rehabilitation Science and Radiology & Biomedical Imaging at the University of California, San Francisco (UCSF), a research group leader in Metabolic Imaging of Neurological disorders, a core member of the UCSF/UCB BioEngineering Graduate Program and of the UCSF Biomedical Science Graduate program, and an investigator of the California Institute for Quantitative Biosciences (QBI). Her research focuses on developing and validating magnetic resonance (MR)-based imaging and spectroscopy methods for in vivo measurement of brain metabolism in preclinical models of neurological disorders, including Multiple Sclerosis, Traumatic Brain Injury, Alzheimer's disease, neuroinflammation and CNS lymphoma. She has internationally recognized expertise in hyperpolarized <sup>13</sup>C MR imaging, and has a particular interest in helping expand the use of HP-based metabolic imaging approaches to the study of neurodegenerative disorders in the clinical setting.

*More info: <http://chaumeillab.ucsf.edu>*

### **"MR metabolic imaging of neurological disorders"**

Since 2003, hyperpolarized (HP) <sup>13</sup>C has been revolutionizing the field of cancer imaging. Through a >10-50,000 increase in the MR signal of <sup>13</sup>C-labeled probes, this methodology can monitor metabolic reactions in real-time in vivo and improve the detection of neoplasms in preclinical models and in cancer patients. More recently, as metabolic impairment plays a crucial role in most brain diseases, HP <sup>13</sup>C MR imaging has proven as a viable tool for imaging neurological disorders. In this webinar, Dr. Myriam Chaumeil will discuss emerging applications for HP-<sup>13</sup>C MRI in detecting and monitoring metabolic impairments and neuroinflammatory processes in preclinical models of brain diseases and will discuss future directions and potential for metabolic imaging to fill current clinical gaps.